Literature DB >> 15201740

Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?

George N Thalmann1, Regula Markwalder, Osama Shahin, Fiona C Burkhard, Werner W Hochreiter, Urs E Studer.   

Abstract

PURPOSE: In this retrospective nonrandomized study we compared the long-term outcome in patients with newly diagnosed stage T1G3 bladder cancer treated with transurethral resection and bacillus Calmette-Guerin or immediate cystectomy.
MATERIALS AND METHODS: Of 121 patients with a median age of 67 years (range 36 to 88) diagnosed with primary T1G3 bladder cancer between 1976 and 1999, 92 were treated by transureteral resection with additional intravesical bacillus Calmette-Guerin and 29 were treated with immediate cystectomy.
RESULTS: Of the 92 patients treated with an organ preserving approach 29 remained disease-free, local recurrence developed in 33 (36%) and progression developed in 30 (33%) at a median followup of 6.9 years (range 0.6 to 16.5). Of these 92 patients 27 (29%) underwent deferred cystectomy at a median of 12.9 months (range 4.8 to 136), of whom 10 (37%) with a median postoperative followup of 19 months (range 2 to 173) died of progressive disease with a median survival of 13 months (range 3 to 34) after cystectomy. The majority of patients who died of progressive disease refused cystectomy, were referred too late for cystectomy, were inoperable or had upper urinary tract disease. Six of the 29 patients (21%) undergoing immediate cystectomy had progression at a median of 13.2 months (range 5.5 to 37). Overall and tumor specific survival at 5 years in patients treated with an organ preserving approach was 69% and 80%, and in those treated with immediate cystectomy it was 54% and 69%, respectively.
CONCLUSIONS: The results of this analysis demonstrate that the concept of an organ preserving approach is acceptable and spares the bladder in approximately half of the patients with primary T1G3 bladder cancer. Of the patients 30% require deferred cystectomy, making meticulous, close followup mandatory.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201740     DOI: 10.1097/01.ju.0000132129.87598.3b

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  27 in total

1.  Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.

Authors:  Haris Zahoor; Maria C Mir; Pedro C Barata; Andrew J Stephenson; Steven C Campbell; Amr Fergany; Robert Dreicer; Jorge A Garcia
Journal:  Invest New Drugs       Date:  2019-06-24       Impact factor: 3.850

2.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

3.  T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.

Authors:  E De Berardinis; G M Busetto; G Antonini; R Giovannone; V Gentile
Journal:  Int Urol Nephrol       Date:  2011-03-29       Impact factor: 2.370

4.  Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.

Authors:  Bin Huang; Gaowei Huang; Wenji Li; Lingwu Chen; Xiaopeng Mao; Junxing Chen
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-22       Impact factor: 4.553

5.  Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness.

Authors:  Shuichiro Kobayashi; Fumitaka Koga; Soichiro Yoshida; Hitoshi Masuda; Chikako Ishii; Hiroshi Tanaka; Yoshinobu Komai; Minato Yokoyama; Kazutaka Saito; Yasuhisa Fujii; Satoru Kawakami; Kazunori Kihara
Journal:  Eur Radiol       Date:  2011-06-18       Impact factor: 5.315

6.  Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.

Authors:  Francesco Soria; Francesca Pisano; Paolo Gontero; J Palou; S Joniau; V Serretta; S Larré; S Di Stasi; B van Rhijn; J A Witjes; A Grotenhuis; R Colombo; A Briganti; M Babjuk; V Soukup; P U Malmstrom; J Irani; N Malats; J Baniel; R Mano; T Cai; E Cha; P Ardelt; J Varkarakis; R Bartoletti; G Dalbagni; S F Shariat; E Xylinas; R J Karnes; R Sylvester
Journal:  World J Urol       Date:  2018-08-31       Impact factor: 4.226

7.  Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer.

Authors:  Faysal A Yafi; Armen G Aprikian; Joseph L Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; Fred Saad; David Bell; Darrel Drachenberg; Wassim Kassouf
Journal:  World J Urol       Date:  2013-11-10       Impact factor: 4.226

8.  Three-gene signature predicts disease progression of non-muscle invasive bladder cancer.

Authors:  Pildu Jeong; Yun-Sok Ha; In-Chang Cho; Seok-Joong Yun; Eun Sang Yoo; Isaac Yi Kim; Yung Hyun Choi; Sung-Kwon Moon; Wun-Jae Kim
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

9.  Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer.

Authors:  Guido Dalbagni; Kinjal Vora; Matthew Kaag; Angel Cronin; Bernard Bochner; S Machele Donat; Harry W Herr
Journal:  Eur Urol       Date:  2009-07-17       Impact factor: 20.096

10.  Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3).

Authors:  Richard E Hautmann; Bjoern G Volkmer; Kilian Gust
Journal:  World J Urol       Date:  2009-03-25       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.